Literature DB >> 15994095

Mutant huntingtin represses CBP, but not p300, by binding and protein degradation.

Shu-Yan Cong1, Barry A Pepers, Bernd O Evert, David C Rubinsztein, Raymund A C Roos, Gert-Jan B van Ommen, Josephine C Dorsman.   

Abstract

Huntington's disease can be used as a model to study neurodegenerative disorders caused by aggregation-prone proteins. It has been proposed that the entrapment of transcription factors in aggregates plays an important role in pathogenesis. We now report that the transcriptional activity of CBP is already repressed in the early time points by soluble mutant huntingtin, whereas the histone acetylase activity of CBP/p300 is gradually diminished over time. Mutant huntingtin bound much stronger to CBP than normal huntingtin, possibly contributing to repression. Especially at the later time points, CBP protein level was gradually reduced via the proteasome pathway. In sharp contrast, p300 was unaffected by mutant huntingtin. This selective degradation of CBP was absent in spinocerebellar ataxia 3. Thus, mutant huntingtin specifically affects CBP and not p300 both at the early and later time points, via multiple mechanisms. In addition to the reduction of CBP, also the altered ratio of these closely related histone acetyltransferases may affect chromatin structure and transcription and thus contribute to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994095     DOI: 10.1016/j.mcn.2005.05.003

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  13 in total

Review 1.  Update on Huntington's disease.

Authors:  Sarah B Berman; J Timothy Greenamyre
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

2.  Modifications of p53 and the DNA damage response in cells expressing mutant form of the protein huntingtin.

Authors:  Jennifer L Illuzzi; Cassie A Vickers; Eric B Kmiec
Journal:  J Mol Neurosci       Date:  2011-04-05       Impact factor: 3.444

3.  Expression of HDAC1 and CBP/p300 in human colorectal carcinomas.

Authors:  Katsuyoshi Ishihama; Mitsunori Yamakawa; Shuho Semba; Hiroaki Takeda; Sumio Kawata; Seishi Kimura; Wataru Kimura
Journal:  J Clin Pathol       Date:  2007-08-24       Impact factor: 3.411

Review 4.  Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function.

Authors:  Ling Wang; Yong Tang; Philip A Cole; Ronen Marmorstein
Journal:  Curr Opin Struct Biol       Date:  2008-10-27       Impact factor: 6.809

Review 5.  The expanding role for chromatin and transcription in polyglutamine disease.

Authors:  Ryan D Mohan; Susan M Abmayr; Jerry L Workman
Journal:  Curr Opin Genet Dev       Date:  2014-08-11       Impact factor: 5.578

6.  Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.

Authors:  Rajnish Kumar Chaturvedi; Thomas Hennessey; Ashu Johri; Shashi Kant Tiwari; Divya Mishra; Swati Agarwal; Yoon Seong Kim; M Flint Beal
Journal:  Hum Mol Genet       Date:  2012-05-15       Impact factor: 6.150

7.  Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities.

Authors:  Sheila K Pirooznia; Felice Elefant
Journal:  Front Cell Neurosci       Date:  2013-03-28       Impact factor: 5.505

Review 8.  Use of epigenetic drugs in disease: an overview.

Authors:  Sarah Heerboth; Karolina Lapinska; Nicole Snyder; Meghan Leary; Sarah Rollinson; Sibaji Sarkar
Journal:  Genet Epigenet       Date:  2014-05-27

9.  Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity.

Authors:  Maria Tsirigotis; R Mitchell Baldwin; Matthew Y Tang; Ian A J Lorimer; Douglas A Gray
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

10.  Histone acetylation and CREB binding protein are required for neuronal resistance against ischemic injury.

Authors:  Ferah Yildirim; Shengbo Ji; Golo Kronenberg; Angel Barco; Roman Olivares; Eva Benito; Ulrich Dirnagl; Karen Gertz; Matthias Endres; Christoph Harms; Andreas Meisel
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.